Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Geodon, Abilify Have Low Diabetes Risk, ADA Says; Lilly Disagrees

Executive Summary

An American Diabetes Association "consensus" statement on antipsychotics and the risk of diabetes may help Pfizer and Bristol-Myers Squibb make the case to FDA to exempt Geodon and Abilify from class labeling

You may also be interested in...



CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM

Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study

CATIE Suggests Zyprexa Useful As Initial Schizophrenia Treatment – NEJM

Results of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study suggest Lilly's Zyprexa may be well suited as initial therapy in the treatment of schizophrenia, according to an editorial accompanying the study

Pfizer Geodon Label Adds Bipolar Claim, Modified Class Diabetes Warning

Pfizer plans to highlight additional data on weight gain among patients treated with other antipsychotics in promoting a new Geodon indication for acute bipolar mania

Related Content

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel